Independent Panel on Evidence for Action against AMR
Designing an Independent Panel on Evidence for Action on Antimicrobial Resistance: Lessons from Selected Bodies in Global Health, Climate Change and Biodiversity
By Viviana Munoz Tellez and Francesca Chiara
This paper proposes a framework for designing an Independent Panel on Evidence for Action on Antimicrobial Resistance (IPEA), responding to the 2025 United Nations General Assembly mandate. Through a comparative analysis of selected international scientific advisory bodies, we identify the panel’s mandate as the foundational element that will critically shape its composition, scope, deliverables, and governance structure. Our framework addresses key domains of credibility, scientific integrity, authority, policy relevance, and sustainability while establishing equity as a fundamental design principle—not merely ensuring low and middle-income country (LMIC) participation but designing the IPEA to address existing imbalances in antimicrobial resistance (AMR) evidence production and dissemination. We analyse potential mandate options, from evidence synthesis to policy recommendations, highlighting the importance of defining a unique and complementary role for IPEA within the existing AMR governance landscape to avoid duplication and maximize impact on global AMR response.
(more…)
Leveraging the Antimicrobial Resistance Declarations of 2024 to Reduce the Burden of Drug-Resistant Infections
By Afreenish Amir & Viviana Munoz Tellez
In 2024, two significant events highlighted the global concern about antimicrobial resistance (AMR). AMR is a pressing global health issue, imperiling public health, economic stability, and societal well-being. The 79th United Nations General Assembly (UNGA) in its special session on AMR and the 4th Ministerial Meeting on AMR have emphasized the need for collective action and international cooperation to mitigate the impact of AMR. The UNGA Declaration has set some targets including reducing global deaths associated with bacterial AMR by 10% by 2030 and enhancing the antimicrobial usage from the World Health Organization (WHO) AWaRe (Access, Watch, Reserve) Access category to 70% by 2030. Accomplishing these targets requires enhancing the inter-ministerial and inter-sectoral collaboration within countries, and the development of strategies reflected in national action plans (NAPs) tailored to each country’s unique dynamics. There are several important commitments made that now need to be implemented, including increased support to countries to develop funded NAPs, the establishment of an Independent Panel on Evidence for Action against AMR, capacity building for local manufacturing of vaccines, therapeutics, diagnostics and essential supplies, developing a new Global Action Plan on AMR by 2026 with a focus on a people centered approach, and advancing cross-sectoral behavioral change interventions. However, these fell short of ambition, particularly in key areas such as financing, reduction of misuse and overuse of antimicrobials in human and animal health and the environment as a vector for AMR. This Policy Brief reviews the new commitments on AMR made in 2024 under the light of current challenges in developing countries and advances recommendations to accelerate progress on AMR.
(more…)
